Butorphanol alleviates lipopolysaccharide‑induced inflammation and apoptosis of cardiomyocytes via activation of the κ‑opioid receptor

Tang,Weiqing; Luo,Liu; Hu,Baoji; Zheng,Mingzhi

doi:10.3892/etm.2021.10683

Butorphanol alleviates lipopolysaccharide‑induced inflammation and apoptosis of cardiomyocytes via activation of the κ‑opioid receptor

Authors:
- Weiqing Tang
- Liu Luo
- Baoji Hu
- Mingzhi Zheng
View Affiliations

Affiliations: Department of Anesthesiology, Shanghai Pudong Hospital, Fudan University Pudong Medical Center, Shanghai 201399, P.R. China, Department of Anesthesiology, The Affiliated Zhuzhou Hospital of Xiangya School of Medicine, Central South University, Zhuzhou Central Hospital, Zhuzhou, Hunan 412000, P.R. China
Published online on: September 2, 2021 https://doi.org/10.3892/etm.2021.10683
Article Number: 1248
Copyright: © Tang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Sepsis‑induced myocardial dysfunction is a leading cause of the high mortality rates associated with sepsis. The aim of the present study was to investigate the effect of butorphanol on sepsis‑induced cardiomyocyte dysfunction. Lipopolysaccharide (LPS) was used to induce H9C2 cardiomyocytes to establish an in vitro sepsis model. The effect of butorphanol on the viability of LPS‑induced H9C2 cells was analyzed using a Cell Counting Kit‑8 assay. The levels of tumor necrosis factor‑α, interleukin (IL)‑1β and IL‑6 were detected using ELISA. Western blotting was used to analyze the expression levels of inflammation‑and apoptosis‑related proteins. Cell apoptosis was measured using a TUNEL assay. The expression levels of κ‑opioid receptor (KOR) were analyzed using reverse transcription‑quantitative PCR analysis and western blotting. Following LPS induction, the levels of inflammatory cytokines and proapoptotic proteins were found to be upregulated in H9C2 cells, while butorphanol treatment downregulated these levels. The expression levels of KOR were also upregulated following butorphanol treatment in LPS‑induced H9C2 cells. Addition of the KOR inhibitor, nor‑binaltorphimine, alleviated the inhibitory effects of butorphanol on inflammation and apoptosis in LPS‑induced H9C2 cells. In conclusion, the findings of the present study provided evidence indicating that butorphanol may alleviate LPS‑induced inflammation and apoptosis in cardiomyocytes by upregulating KOR expression, which may provide a novel insight into the potential therapeutic effects of butorphanol and its underlying mechanism of action.

View Figures

View References

1	Kaukonen KM, Bailey M, Pilcher D, Cooper DJ and Bellomo R: Systemic inflammatory response syndrome criteria in defining severe sepsis. N Engl J Med. 372:1629–1638. 2015.PubMed/NCBI View Article : Google Scholar
2	Delano MJ and Ward PA: Sepsis-induced immune dysfunction: Can immune therapies reduce mortality? J Clin Invest. 126:23–31. 2016.PubMed/NCBI View Article : Google Scholar
3	Gaieski DF, Edwards JM, Kallan MJ and Carr BG: Benchmarking the incidence and mortality of severe sepsis in the United States. Crit Care Med. 41:1167–1174. 2013.PubMed/NCBI View Article : Google Scholar
4	Dombrovskiy VY, Martin AA, Sunderram J and Paz HL: Rapid increase in hospitalization and mortality rates for severe sepsis in the United States: A trend analysis from 1993 to 2003. Crit Care Med. 35:1244–1250. 2007.PubMed/NCBI View Article : Google Scholar
5	Keeley A, Hine P and Nsutebu E: The recognition and management of sepsis and septic shock: A guide for non-intensivists. Postgrad Med J. 93:626–634. 2017.PubMed/NCBI View Article : Google Scholar
6	Lv X and Wang H: Pathophysiology of sepsis-induced myocardial dysfunction. Mil Med Res. 3(30)2016.PubMed/NCBI View Article : Google Scholar
7	Yao Y, Sun F and Lei M: miR-25 inhibits sepsis-induced cardiomyocyte apoptosis by targetting PTEN. Biosci Rep. 38(38)2018.PubMed/NCBI View Article : Google Scholar
8	Hua J, Miao S, Shi M, Tu Q, Wang X, Liu S, Wang G and Gan J: Effect of butorphanol on etomidate-induced myoclonus: A systematic review and meta-analysis. Drug Des Devel Ther. 13:1213–1220. 2019.PubMed/NCBI View Article : Google Scholar
9	Dawn AG and Yosipovitch G: Butorphanol for treatment of intractable pruritus. J Am Acad Dermatol. 54:527–531. 2006.PubMed/NCBI View Article : Google Scholar
10	Bailey AG, Valley RD, Freid EB and Calhoun P: Epidural morphine combined with epidural or intravenous butorphanol for postoperative analgesia in pediatric patients. Anesth Analg. 79:340–344. 1994.PubMed/NCBI View Article : Google Scholar
11	Gunter JB, McAuliffe J, Gregg T, Weidner N, Varughese AM and Sweeney DM: Continuous epidural butorphanol relieves pruritus associated with epidural morphine infusions in children. Paediatr Anaesth. 10:167–172. 2000.PubMed/NCBI View Article : Google Scholar
12	Heel RC, Brogden RN, Speight TM and Avery GS: Butorphanol: A review of its pharmacological properties and therapeutic efficacy. Drugs. 16:473–505. 1978.PubMed/NCBI View Article : Google Scholar
13	Hoskin PJ and Hanks GW: Opioid agonist-antagonist drugs in acute and chronic pain states. Drugs. 41:326–344. 1991.PubMed/NCBI View Article : Google Scholar
14	Zhang J, Miao S, Tu Q, Shi M, Zou L, Liu S and Wang G: Effect of butorphanol on opioid-induced cough: A meta-analysis of randomized controlled trials. Drug Des Devel Ther. 12:3263–3268. 2018.PubMed/NCBI View Article : Google Scholar
15	Garrity K, Jang A and Wagner S: Butorphanol use in laboring patients with preeclampsia or chronic hypertension. Pregnancy Hypertens. 6:288–290. 2016.PubMed/NCBI View Article : Google Scholar
16	Wang H, Wang JL, Ren HW, He WF and Sun M: Butorphanol protects on myocardial ischemia/reperfusion injury in rats through MAPK signaling pathway. Eur Rev Med Pharmacol Sci. 23:10541–10548. 2019.PubMed/NCBI View Article : Google Scholar
17	Huang LH, Li J, Gu JP, Qu MX, Yu J and Wang ZY: Butorphanol attenuates myocardial ischemia reperfusion injury through inhibiting mitochondria-mediated apoptosis in mice. Eur Rev Med Pharmacol Sci. 22:1819–1824. 2018.PubMed/NCBI View Article : Google Scholar
18	Meng J, Jiang SJ, Jiang D and Zhao Y: Butorphanol attenuates inflammation via targeting NF-κB in septic rats with brain injury. Eur Rev Med Pharmacol Sci. 23 (Suppl 3):161–170. 2019.PubMed/NCBI View Article : Google Scholar
19	Baradaran Rahim V, Khammar MT, Rakhshandeh H, Samzadeh-Kermani A, Hosseini A and Askari VR: Crocin protects cardiomyocytes against LPS-Induced inflammation. Pharmacol Rep. 71:1228–1234. 2019.PubMed/NCBI View Article : Google Scholar
20	Cui Y, Feng N, Gu X, Fu F, Li J, Guo H, Liu Y, Zhang S, Li J, Wang Y, et al: κ-Opioid receptor stimulation reduces palmitate-induced apoptosis via Akt/eNOS signaling pathway. Lipids Health Dis. 18(52)2019.PubMed/NCBI View Article : Google Scholar
21	Kenneth JL and Thomas DS: Analysis of relative gene expression data using real-time quantitative PCR and the 2-ΔΔCT method. Methods. 25:402–408. 2002.PubMed/NCBI View Article : Google Scholar
22	Liang W, Li J, Bai C, Chen Y, Li Y, Huang G and Wang X: Interleukin-5 deletion promotes sepsis-induced M1 macrophage differentiation, deteriorates cardiac dysfunction, and exacerbates cardiac injury via the NF-κB p65 pathway in mice. Biofactors. 46:1006–1017. 2020.PubMed/NCBI View Article : Google Scholar
23	Yang C, Xia W, Liu X, Lin J and Wu A: Role of TXNIP/NLRP3 in sepsis-induced myocardial dysfunction. Int J Mol Med. 44:417–426. 2019.PubMed/NCBI View Article : Google Scholar
24	Ji J, Lin W, Vrudhula A, Xi J, Yeliseev A, Grothusen JR, Bu W and Liu R: Molecular interaction between butorphanol and κ-opioid receptor. Anesth Analg. 131:935–942. 2020.PubMed/NCBI View Article : Google Scholar
25	Pulido JN, Afessa B, Masaki M, Yuasa T, Gillespie S, Herasevich V, Brown DR and Oh JK: Clinical spectrum, frequency, and significance of myocardial dysfunction in severe sepsis and septic shock. Mayo Clin Proc. 87:620–628. 2012.PubMed/NCBI View Article : Google Scholar
26	Hoffert MJ, Couch JR, Diamond S, Elkind AH, Goldstein J, Kohlerman NJ III, Saper JR and Solomon S: Transnasal butorphanol in the treatment of acute migraine. Headache. 35:65–69. 1995.PubMed/NCBI View Article : Google Scholar
27	Afulukwe IF, Cohen RI, Zeballos GA, Iqbal M and Scharf SM: Selective NOS inhibition restores myocardial contractility in endotoxemic rats; however, myocardial NO content does not correlate with myocardial dysfunction. Am J Respir Crit Care Med. 162:21–26. 2000.PubMed/NCBI View Article : Google Scholar
28	Cohen RI, Wilson D and Liu SF: Nitric oxide modifies the sarcoplasmic reticular calcium release channel in endotoxemia by both guanosine-3',5' (cyclic) phosphate-dependent and independent pathways. Crit Care Med. 34:173–181. 2006.PubMed/NCBI View Article : Google Scholar
29	Chagnon F, Bentourkia M, Lecomte R, Lessard M and Lesur O: Endotoxin-induced heart dysfunction in rats: Assessment of myocardial perfusion and permeability and the role of fluid resuscitation. Crit Care Med. 34:127–133. 2006.PubMed/NCBI View Article : Google Scholar
30	Walley KR: Sepsis-induced myocardial dysfunction. Curr Opin Crit Care. 24:292–299. 2018.PubMed/NCBI View Article : Google Scholar
31	Su Q, Li L, Sun Y, Yang H, Ye Z and Zhao J: Effects of the TLR4/Myd88/NF-κB signaling pathway on NLRP3 inflammasome in coronary microembolization-induced myocardial injury. Cell Physiol Biochem. 47:1497–1508. 2018.PubMed/NCBI View Article : Google Scholar
32	Commiskey S, Fan LW, Ho IK and Rockhold RW: Butorphanol: Effects of a prototypical agonist-antagonist analgesic on kappa-opioid receptors. J Pharmacol Sci. 98:109–116. 2005.PubMed/NCBI View Article : Google Scholar
33	Xie GX, Meng F, Mansour A, Thompson RC, Hoversten MT, Goldstein A, Watson SJ and Akil H: Primary structure and functional expression of a guinea pig kappa opioid (dynorphin) receptor. Proc Natl Acad Sci USA. 91:3779–3783. 1994.PubMed/NCBI View Article : Google Scholar
34	Yasuda K, Espinosa R III, Takeda J, Le Beau MM and Bell GI: Localization of the kappa opioid receptor gene to human chromosome band 8q11.2. Genomics. 19:596–597. 1994.PubMed/NCBI View Article : Google Scholar
35	Xu J, Chen F, Wang S, Akins NS, Hossain MI, Zhou Y, Huang J, Ji J, Xi J, Lin W, et al: Kappa opioid receptors internalization is protective against oxygen-glucose deprivation through β-arrestin activation and Akt-mediated signaling pathway. Neurochem Int. 137(104748)2020.PubMed/NCBI View Article : Google Scholar
36	Simonin F, Slowe S, Becker JA, Matthes HW, Filliol D, Chluba J, Kitchen I and Kieffer BL: Analysis of [3H]bremazocine binding in single and combinatorial opioid receptor knockout mice. Eur J Pharmacol. 414:189–195. 2001.PubMed/NCBI View Article : Google Scholar
37	Chang KJ, Hazum E and Cuatrecasas P: Novel opiate binding sites selective for benzomorphan drugs. Proc Natl Acad Sci USA. 78:4141–4145. 1981.PubMed/NCBI View Article : Google Scholar
38	Chéret J, Gherardini J, Soeberdt M, Hundt JE, Abels C, Bertolini M and Paus R: Non-neuronal kappa-opioid receptor activation enhances epidermal keratinocyte proliferation, and modulates mast cell functions in human skin ex vivo. J Dermatol. 47:917–921. 2020.PubMed/NCBI View Article : Google Scholar
39	Wang K, Liu Z, Zhao M, Zhang F, Wang K, Feng N, Fu F, Li J, Li J, Liu Y, et al: κ-opioid receptor activation promotes mitochondrial fusion and enhances myocardial resistance to ischemia and reperfusion injury via STAT3-OPA1 pathway. Eur J Pharmacol. 874(172987)2020.PubMed/NCBI View Article : Google Scholar